Navigation Links
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
Date:3/23/2009

BEIJING, March 23 /PRNewswire/ -- BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.

BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help enhance internal drug discovery and shorten development timelines.

"After a successful collaboration involving discovery chemistry, ADMET, and DMPK, AstraZeneca has expanded its collaboration with BioDuro to leverage the strengths of its team to help develop new therapeutics," said Lena Martensson Director of Strategic Planning and Business Development.

"BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at AstraZeneca to develop new clinical compounds for Respiratory and Inflammation indications. This partnership demonstrates the strength of our innovation, quality, and our fully integrated R&D service platform," commented John Oyler, Chief Executive Officer and co-founder of BioDuro LLC.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

About BioDuro

BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of 580 in Beijing, China. BioDuro combines western pharmaceutical company quality and professionalism, with entrepreneurial, innovative biotech culture, to leverage its talented, hard-working Chinese scientists. BioDuro's clients are over 40 pharmaceutical and biotechnology companies, including 10 of the top-12. BioDuro's services span the entire range of drug discovery and development, from discovery chemistry, discovery biology, early ADMET, DMPK, through pharmacology and drug safety and evaluation.

*ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity

**DMPK: Drug Metabolism and Pharmacokinetics


'/>"/>
SOURCE BioDuro, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation
2. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
3. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
4. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
5. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
6. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
7. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
8. Melior Enters Research Collaboration with AstraZeneca
9. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
10. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
11. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):